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 2 
ABSTRACT 1 
There is a clear requirement for an accurate SARS-CoV-2 antibody test, both as a complement 2 
to existing diagnostic capabilities and for determining community seroprevalence. We 3 
therefore evaluated the performance of a variety of antibody testing technologies and their 4 
potential use as diagnostic tools. Highly specific in-house ELISAs were developed for the 5 
detection of anti-spike (S), -receptor binding domain (RBD) and -nucleocapsid (N) antibodies 6 
and used for the cross-comparison of ten commercial serological assays – a 7 
chemiluminescence-based platform, two ELISAs and seven colloidal gold lateral flow 8 
immunoassays (LFIAs) – on an identical panel of 110 SARS-CoV-2-positive samples and 50 pre-9 
pandemic negatives. There was a wide variation in the performance of the different 10 
platforms, with specificity ranging from 82% to 100%, and overall sensitivity from 60.9% to 11 
87.3%.  However, the head-to-head comparison of multiple sero-diagnostic assays on 12 
identical sample sets revealed that performance is highly dependent on the time of sampling, 13 
with sensitivities of over 95% seen in several tests when assessing samples from more than 14 
20 days post onset of symptoms. Furthermore, these analyses identified clear outlying 15 
samples that were negative in all tests, but were later shown to be from individuals with 16 
mildest disease presentation. Rigorous comparison of antibody testing platforms will inform 17 
the deployment of point-of-care technologies in healthcare settings and their use in the 18 
monitoring of SARS-CoV-2 infections.  19 
 3 
 1 
INTRODUCTION 2 
 3 
As of the 1st of June 2020, over 6 million cases of SARS-CoV-2 have been confirmed worldwide, 4 
accounting for more than 370,000 deaths (https://covid19.who.int/). Lack of treatments or 5 
vaccines have forced governments to adopt strict quarantine strategies in an attempt to 6 
control the spread of the virus, causing major economical disturbances as well as adversely 7 
affecting quality of life and healthcare provision. 8 
 9 
Current guidelines by leading health bodies, including the Centers for Disease Control and 10 
Prevention (CDC) in the US and Public Health England (PHE) in the UK, recommend SARS-CoV-11 
2 diagnosis from upper or lower respiratory specimens (including nasopharyngeal swabs and 12 
bronchoalveolar lavage) using real-time RT-PCR, typically targeting the nucleocapsid (N) or 13 
RNA-dependent RNA polymerase (RdRp) genes [1,2]. These tests are highly sensitive - capable 14 
of detecting vestigial viral RNA levels - and are optimal for the early detection of the virus. 15 
However, the performance of the test is dependent on the time the sample is collected, with 16 
viral load declining after the first week of symptoms [3,4]. 17 
 18 
There is, therefore, a clear requirement for accurate serology testing as a companion 19 
diagnostic to PCR-based testing.  This is highlighted by the recent appearance of clusters of 20 
paediatric inflammatory multisystem syndrome (PIMS) and other hyperimmune reactions 21 
associated with SARS-CoV-2 infection [5-7]. Presentation is delayed relative to active viral 22 
infection, with the detection of antibody responses being key to clinical diagnosis. In addition, 23 
monitoring population seroprevalence will be central to future public health planning based 24 
on disease susceptibility and herd immunity [8]. For this to be meaningful, it is imperative 25 
that antibody detection methods are affordable, reliable, and readily accessible.  26 
 27 
However, with an incomplete knowledge of the immunology of COVID-19, evaluating tests 28 
with the assumption that antibodies ‘should’ be there, and comparatively to RT-PCR, is 29 
problematic. Head-to-head comparisons of multiple sero-diagnostic assays on identical 30 
samples therefore provides a robust assessment of individual assay performance. 31 
Accordingly, we developed a highly specific semi-quantitative ELISA for the detection of anti-32 
 4 
spike (S), -S receptor binding domain (RBD) and -N antibodies, and used this to cross-evaluate 1 
ten commercial antibody tests (seven lateral flow immunoassays (LFIAs), one 2 
chemiluminescent assay and two ELISAs) on a collection of 110 serum samples from 3 
confirmed RNA positive patients, and 50 pre-pandemic samples from March 2019. Our results 4 
demonstrate a wide variation in the performance of the different platforms, ranging from 5 
60.9% to 87.3% sensitivity and from 82% to 100% specificity. As expected, performance is 6 
highly dependent on the time the sample was taken post onset of symptoms (POS) and 7 
disease severity. Results obtained in this work have enabled the diagnostic-grade validation 8 
for one of the LFIAs evaluated for pilot clinical use for adult and paediatric patients with a 9 
range of clinically-suspected COVID-19 inflammatory syndromes at Guy’s and St Thomas’ 10 
Hospitals. 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
  20 
 5 
RESULTS 1 
 2 
Study samples 3 
110 serum samples collected from 87 individuals between the 4th of March and 21st of April 4 
2020 at St Thomas’ Hospital were used to compare a panel of serological assays. At the time 5 
of study, UK government guidelines limited SARS-CoV-2 testing to individuals requiring 6 
hospitalisation, and all 87 individuals had RT-PCR-confirmed SARS-CoV-2 infection.  Samples 7 
were representative of typical hospital admissions during the period, with a spectrum of 8 
clinical severities from mild (requiring no respiratory support) to critical (requiring extra-9 
corporeal membrane oxygenation (ECMO)), and a range of time points after self-reported 10 
onset of symptoms (1 to 30 days) (Table 1).  11 
 12 
In-house ELISA development 13 
In-house ELISAs were developed to measure antibody responses against the full-length S, the 14 
RBD and N. Recombinant S and RBD were expressed in HEK 293F cells and purified by affinity 15 
and size exclusion chromatography. N was expressed in and purified from E. coli. A total of 16 
320 pre-pandemic serum samples from several cohorts were used to determine the lower 17 
limit of the assay, including sera from individuals attending St Thomas’ Hospital in March 18 
2019, sera from vaccination studies, cancer patients, healthy volunteers, and individuals with 19 
acute EBV infection (Supplementary Table 1). Samples from hospital patients with confirmed 20 
SARS-CoV-2 infection (from the described serum samples in Table 1) were used as positive 21 
controls. All 24 serum samples from PCR positive ICU patients taken at least 10 days post 22 
symptoms showed strong IgG binding to S, RBD and N (Figure 1, Supplementary Table 1). In 23 
contrast, although high IgM reactivity was also observed to S and RBD in some individuals, 24 
only 5 of the 320 negative control samples showed IgG reactivity to S or RBD (Figure 1, 25 
Supplementary Table 1). High IgM and IgG reactivity was observed in the pre-pandemic 26 
samples against N (Figure 1) suggestive of potential cross-reaction with seasonal 27 
coronaviruses. Of note, all individuals with acute EBV infection had high IgM reactivity to N 28 
and RBD. Importantly, none of the pre-COVID sera had detectable IgG binding to N and S or 29 
N and RBD. Taking into account the reactivity of negative control samples in this ELISA, 100% 30 
specificity could be reached using a cut-off where IgG against N or S both have OD values at 31 
 6 
least 4-fold above the wells containing secondary antibody only (Figure 1B, Supplementary 1 
Table 1).   2 
 3 
Comparison of serological tests 4 
All serological assays were evaluated with the same set of 110 serum samples from confirmed 5 
SARS-CoV-2-positive individuals.  Each of the samples was tested: for anti-SARS-CoV-2 IgM by 6 
in-house ELISA and seven LFIAs; for IgA by commercial ELISA (Figure 2); and for IgG by in-7 
house ELISA, seven LFIAs, a commercial ELISA and for total antibody (IgG, IgM and IgA) using 8 
a chemiluminescent assay (Figure 3). The commercial ELISAs detect anti-S1 antibodies; for 9 
the LFIAs this is undisclosed proprietary information, but for some of the tests is known to be 10 
S. With no existing standardised diagnostic test for the assessment of the serological response 11 
to SARS-CoV-2, we started by comparing commercial serological assays with the configuration 12 
of the in-house ELISA most likely to represent antibodies detected by the commercial tests 13 
(detection of anti-S IgM and IgG antibodies), and that had high specificity and sensitivity 14 
(Supplementary Table 1). For the purpose of illustration, the intensity of bands shown in a 15 
positive LFIA test, or signal strength in commercial ELISA or chemiluminescent assay, is 16 
reproduced as a heatmap. However, the visible detection of a band or result above a given 17 
manufacturer’s threshold scored as a positive result regardless of classification. For samples 18 
giving a strong response by ELISA (> 9-fold), the majority of the commercial assays show a 19 
consensus positive result. Weaker antibody responses yielded mixed results from the LFIAs, 20 
with a clear pattern of increasing detection of antibodies seen across all tests with increasing 21 
time POS. Samples from days 1-9 gave an extremely mixed picture, indicative of an early 22 
evolving immune response.  For the detection of IgM, 11 of the 72 samples from days 10 or 23 
more POS were negative by anti-S ELISA.  5 of these 11 samples were positive, in some cases 24 
only weakly, for at least two LFIAs and/or IgA. The remaining 6 were negative in at least 6 LFIA 25 
tests and for IgA (indicated with a yellow circle in Figure 2).  These same 6 samples were 26 
negative for IgG by in-house and commercial ELISA, in all 7 LFIAs and by chemiluminescent 27 
assay (indicated with a yellow circle in Figure 3). Importantly, all 6 samples came from 28 
individuals with a disease severity score of 0. Later time points were obtained for three of 29 
these individuals (both of the day 10 samples and the sixth day 14 sample) and the next 30 
available samples were found to be strongly positive for IgG and IgM by LFIA (days 47, 77 and 31 
51 POS, respectively). Further investigation into the nature of the negative day 23 sample 32 
 7 
revealed that it was an error in self-reporting the time of symptom onset: this individual had 1 
COVID-19-compatible symptoms for 23 days prior to sampling, yet tested negative for RNA 2 
10 days POS. 21 days POS the individual tested positive for RNA, therefore the more likely 3 
time of sampling was between 2 and 12 days POS.  Samples were not re-classified, as they are 4 
representative of the real-time analyses being performed during the peak of a pandemic. 5 
However, the day 23 sample was omitted from sensitivity calculations. 6 
 7 
Overall, with the exception of GenBody and Watmind, all tests gave cross-assay agreements 8 
between 81.8 and 95.4% (Figure 4 and Supplementary Figure A).  The highest level of 9 
agreement was seen between the in-house ELISA, SureScreen, Accu-Tell, Spring and 10 
EUROIMMUN tests. Interestingly, the in-house ELISA IgM and EUROIMMUN IgA results 11 
showed particularly good agreement (94.5%), although the EUROIMMUN detected IgA more 12 
frequently in early samples compared with the IgM detected by in-house ELISA (Figure 2). 13 
 14 
Assay specificity and sensitivity 15 
Results from the 110 SARS-CoV-2-positive samples and an identical set of 50 pre-pandemic 16 
negative samples were used to evaluate assay sensitivities and specificities, with extended  17 
specificity assessments using larger sample numbers performed on selected tests (Figure 5A, 18 
Supplementary Figure B and Supplementary Tables 2-5). Cross comparison of overall 19 
specificities and sensitivities led to the shortlisting of six tests with the highest specificity and 20 
sensitivity (ELISA IgM and IgG, SureScreen, Accu-Tell, Spring and EUROIMMUN IgA). These 21 
were the same tests that gave the best agreement in the cross-assay comparisons. Notably, 22 
sensitivity increased for all tests with increasing days POS, with antibodies being variably 23 
detected at early times (Figure 5B). Deep Blue, Accu-Tell, SureScreen and Spring also 24 
displayed the highest levels of sensitivity at less than 10 days. In sum, Deep Blue, Accu-Tell, 25 
SureScreen, Spring, Biohit, Medomics, EUROIMMUN (IgA and IgG) and in-house ELISAs (IgM 26 
and IgG) all had sensitivities above 95% for samples taken ³20 days POS. 27 
 28 
Association of antibody detection with days POS and severity of disease 29 
Sample-by-sample analyses of multiple serological assays showed a trend for increasing 30 
detection of antibodies with increasing days POS (up to 30). We also observed that individuals 31 
with severe disease had a more readily detectable antibody response, particularly compared 32 
 8 
to those who had a brief hospital stay with minimal intervention. Samples were grouped 1 
according to days POS and clinical severity, and compared for anti-S IgM and IgG by in-house 2 
ELISA. Significant differences in antibody levels were observed with increases in both days 3 
and severity, although there was no association between days and severity themselves 4 
(Figure 6A). To assess the development of the antibody response in sequential samples from 5 
the same individual, and to evaluate the ability of LFIAs to detect nuances in antibody 6 
response, longitudinal samples (from individuals with disease severity scores of 4) were 7 
tested by one of the best performing LFIAs (SureScreen) and in-house ELISA (Figure 6B and 8 
C). A similar pattern of detection was seen for both types of assay, with IgM detectable earlier 9 
than IgG, and both tests showing consensus for the strength and timing of the response. 10 
  11 
 9 
DISCUSSION 1 
 2 
This study describes the development of six in-house ELISA configurations for the detection 3 
of IgM and IgG against SARS-CoV-2 S, RBD and N. Anti-S and -N IgG attained specificities of up 4 
to 99% - 100% when results for both targets are combined - and sensitivities of up to 96%.  5 
We used this semi-quantitative platform to cross-evaluate seven LFIAs, a chemiluminescent 6 
test and two commercial ELISAs. Importantly, the availability of sequential serum samples 7 
from patients admitted from the start of the outbreak under an existing ethics agreement for 8 
storage and analysis of surplus amounts of routinely collected clinical samples, enabled us to 9 
conduct this detailed study including examining assay sensitivity with respect to time POS. 10 
 11 
Our analysis demonstrates a broad range of performance across the different platforms, with 12 
several commercial tests performing above 98% specificity. We found that all platforms 13 
showed highest sensitivity, with narrowest confidence limits, in samples taken 20 days POS, 14 
with most tests reaching a value of over 95% (Figure 5B). When all commercial tests were 15 
compared, Accu-Tell, SureScreen and Spring demonstrated highest sensitivity at earlier time 16 
points, while maintaining specificities of 98% or above. These tests also gave the best cross-17 
assay agreements with each other and with the in-house ELISA. In the best-performing tests, 18 
we also observed that signal strength aligned with that seen by ELISA; this was further 19 
supported by the sequential signal increase seen in longitudinal samples from five individuals. 20 
 21 
We approached this study with the intention that an unbiased and transparent comparison 22 
will be of broad value to the scientific and infection diagnostics communities, both in terms 23 
of naming and comparing the kits, and in the nature of the samples likely to be encountered 24 
in hospitals during a SARS-CoV-2 outbreak. Few studies have been published to date in which 25 
multiple LFIAs and ELISAs have been evaluated side-by-side with named kits [9-10]; and in 26 
those that have, only one test overlaps with our study, Deep Blue [9]. Early reports stating 27 
that LFIAs have insufficient sensitivity may have been due to testing samples from mixed time 28 
points and disease severities, or tests that differ from those evaluated here [11]. 29 
 30 
The strength of our study is the head-to-head evaluation of multiple tests on identical serum 31 
samples. The sample set was not compiled retrospectively for the purpose of evaluation, but 32 
 10 
was part of an ongoing process to deploy a serological assay to broaden diagnostic capability 1 
at Guy’s and St Thomas’ Hospitals during the peak of the SARS-CoV-2 epidemic in London. 2 
These samples are therefore entirely representative of the type that will be encountered by 3 
hospital laboratories, and the challenges associated with variable time to seroconversion and 4 
errors in self-reporting onset of symptoms are real. The cross-evaluation of multiple tests 5 
enabled the identification of samples that were negative in every test performed, despite the 6 
fact that samples were taken at 10 days POS or later. While this could highlight a characteristic 7 
of COVID-19 where a subset of patients do not produce a detectable antibody response, we 8 
have evidence that in three cases (the two day 10 samples and sixth day 14) where later 9 
samples were available (47, 77 and 51 days POS, respectively; the only next available samples) 10 
both IgM and IgG antibodies were detected in several LFIAs. In another case (sample at day 11 
23 POS), we uncovered a likely error in self-reported symptom onset and the sample could 12 
actually range anywhere between 2 and 11 days POS. It is important to note that all of the six 13 
unexpectedly negative samples were from COVID-19 cases classified as severity level 0. The 14 
fact that several post-day 10 samples were negative in all serological tests has practical 15 
implications for the use of such assays in diagnostic settings, and thought should be given to 16 
the meaning of a negative result. It also implies that serological surveys are likely to 17 
underestimate the level of exposure to SARS-CoV-2, and the wide variation in the detection 18 
of antibodies, both in terms of time and disease severity, casts into doubt the utility of 19 
“immunity passports”. However, although it is unclear at present whether detection of 20 
antibodies to SARS-CoV-2 indicates protection against future infection, measurement of 21 
antibodies to S, rather than N, is likely to better predict neutralisation function.   22 
 23 
In agreement with previous studies demonstrating a relationship between disease severity 24 
and antibody titres [12-14], we observed a significant increase in detection of antibodies with 25 
increased severity of symptoms (Figure 6A).  Importantly, this correlation is not explained by 26 
a concomitant increase in the days POS of the sample. Therefore, before deployment in 27 
situations where the pre-test prevalence is likely to be low, such as seroprevalence studies, 28 
out-patient assessment or pre-admission screening for operations, these assays will require 29 
further evaluation with known SARS-CoV-2 asymptomatic and ambulatory cases, alongside 30 
an extended set of pre-pandemic samples. This is a priority as countries navigate their way 31 
out of lockdown and move towards living with the ongoing threat of SARS-CoV-2, and 32 
 11 
seroprevalence studies will be important in the implementation and management of safe 1 
public health policies. To maintain the high specificity of our in-house ELISA in community 2 
cohorts where PCR status is unknown, we would recommend determining seropositivity 3 
based on IgG to both N and S.  Sequential or alternate detection of IgM, IgA and IgG may also 4 
provide information on the history of infection. In the only IgA test that we evaluated 5 
(EUROIMMUN), specificity was high while also showing a strong signal in early samples and a 6 
good overall sensitivity.  Detection of IgA in serum, and potentially even earlier by mucosal 7 
sampling, may be a useful diagnostic tool.  8 
 9 
Next generation antibody tests may improve on those currently being trialled, but our results 10 
demonstrate that LFIAs may have utility in a hospital setting as of now, particularly if deployed 11 
where a rapid result could aide a clinical pathway or decision in real time, such as ward 12 
location or prioritisation of further diagnostics and follow up. The ease of use and affordability 13 
of the LFIAs weighs heavily in their favour, especially for potential in resource-poor settings 14 
or as point-of-care solutions in hospitals. Choosing the tests with the highest specificity will 15 
translate to confidence in a positive test result in the clinic; negative or borderline cases may 16 
be tested serially or used together with ELISA testing [15]. Combination testing, in parallel 17 
with RT-PCR, and serial or sequential testing, would provide diagnostic solutions to the 18 
delayed-onset syndromes such as PIMS that are increasingly being reported post-peak 19 
pandemic [5-7].  Further evaluations of candidate tests should be performed prior to use in 20 
clinical settings, ideally tailored to the intended usage and likely pre-test prevalence. A 21 
limitation of our study was the restricted number of pre-pandemic negative and confounding 22 
samples used to cross-validate the commercial kits, and further specificity and sensitivity 23 
studies with a shortlisted group of commercial tests are currently in progress. It will be 24 
particularly important to evaluate samples from individuals infected with other human 25 
coronaviruses or respiratory viruses for potential cross-reacting antibodies. A further 26 
consideration that should be given for healthcare service deployment in the hospital or 27 
community setting is consistency of use. Although the LFIAs are marketed as home testing 28 
kits, in our experience user assiduity is essential to their optimal performance, particularly 29 
when scoring borderline cases and considering need for two independent readers. There will 30 
also likely be need to evaluate alternative sources of blood collection, particularly pin-prick 31 
 12 
collection, and even different samples such as saliva, all of which should be fully evaluated 1 
before deployment. 2 
 3 
In summary, our study compares the performance of 10 commercially available platforms and 4 
several combinations of in-house methods for the detection of anti-SARS-CoV-2 antibodies in 5 
serum samples. Although LFIAs lack the semi-quantitative information provided by ELISA 6 
tests, they have a clear utility advantage over ELISA or chemiluminescence-based 7 
technologies. Shortlisted tests, combined with confirmatory reflex testing using our in-house 8 
ELISA, are now being taken forward into extended validations as part of a pilot clinical service 9 
at Guy’s and St Thomas’ Hospitals. These incremental steps keeping different technologies in 10 
scope, whilst multiple different use-cases are still being defined, will help determine the 11 
clinical utility and cost-effectiveness of COVID-19 serological testing in healthcare settings 12 
both in the hospital and the community. 13 
 14 
 15 
 16 
 17 
  18 
 13 
MATERIALS & METHODS 1 
 2 
Patient overview and sample origin 3 
110 individual venous serum samples collected at St Thomas’ Hospital, London from 87 4 
patients diagnosed as SARS-CoV-2 positive via real-time RT-PCR, were obtained for serological 5 
analysis. Samples ranged from 1 to 30 days after onset of self-reported symptoms. For the 6 
longitudinal study 17 serum samples (6-24 days after symptoms onset) were obtained from 5 7 
patients (3-4 samples each) with confirmed COVID-19 diagnosis. Two patients overlapped 8 
between the longitudinal study and validation study meaning in total there are 90 unique 9 
patients between both studies. Patient information is given in Table 1.  10 
 11 
Pre-pandemic negative samples 12 
320 pre-pandemic serum or plasma samples from various collections were used as negative 13 
controls for the initial development of the in-house ELISA. These included emergency 14 
admissions to St Thomas’ hospital in March 2019 (STH healthy, n=105), individuals with acute 15 
EBV infection (n=9), plasma samples collected from individuals 7 days following immunisation 16 
with an H1N1 vaccine (as part of the HIRD trial [16]) obtained from the KCL Infectious Diseases 17 
Biobank (n=44), cancer patients (n=61), and healthy volunteers (UCL healthy, n=101). An 18 
identical panel of 50 pre-pandemic serum samples from 50 patients, obtained at St Thomas’ 19 
Hospital in March 2019 and taken from the “STH healthy cohort”, were used for head-to-head 20 
specificity calculations for all commercial tests, with an extended panel of 105 samples used 21 
to calculate specificity of the in-house IgM and IgS S ELISA. Further samples from emergency 22 
admissions to St Thomas’ hospital in March 2019 (STH healthy) were used for the extended 23 
validations of four LFIAs (SureScreen, Spring, Biohit and Medomics).  24 
 25 
COVID-19 severity classification 26 
Patients diagnosed with COVID-19 were classified as follows: 27 
0 - asymptomatic OR no requirement for supplemental oxygen. 28 
1 - requirement for supplemental oxygen (FiO2 <0.4) for at least 12 hrs. 29 
2 - requirement for supplemental oxygen (FiO2 ≥0.4) for at least 12 hrs. 30 
3 - requirement for non-invasive ventilation (NIV)/ continuous positive airways pressure 31 
(CPAP) OR proning OR supplemental oxygen (FiO2 >0.6) for at least 12 hrs AND not a 32 
candidate for escalation above level 1 care. 33 
 14 
4 - requirement for intubation and mechanical ventilation OR supplemental oxygen (FiO2 1 
>0.8) AND peripheral oxygen saturations <90% (with no history of type 2 respiratory failure 2 
(T2RF)) OR <85% (with known T2RF) for at least 12 hrs. 3 
5 - requirement for ECMO. 4 
 5 
ELISA protocol 6 
All sera/plasma was heat-inactivated at 56°C for 30 mins before use in the in-house ELISA. 7 
High-binding ELISA plates (Corning, 3690) were coated with antigen (N, S or RBD) at 3 µg/mL 8 
(25 µL per well) in PBS, either overnight at 4°C or 2 hr at 37°C. Wells were washed with PBS-9 
T (PBS with 0.05% Tween-20) and then blocked with 100 µL 5% milk in PBS-T for 1 hr at room 10 
temperature. Wells were emptied and sera and plasma diluted at 1:50 and 1:25 respectively 11 
in milk were added and incubated for 2 hr at room temperature. Control reagents included 12 
CR3009 (2 µg/mL), CR3022 (0.2 µg/mL), negative control plasma (1:25 dilution), positive 13 
control plasma (1:50) and blank wells. Wells were washed with PBS-T. Secondary antibody 14 
was added and incubated for 1 hr at room temperature. IgM was detected using Goat-anti-15 
human-IgM-HRP (1:1,000) (Sigma: A6907) and IgG was detected using Goat-anti-human-Fc-16 
AP (1:1,000) (Jackson: 109-055-043-JIR). Wells were washed with PBS-T and either AP 17 
substrate (Sigma) was added and read at 405 nm (AP) or 1-step TMB substrate (Thermo 18 
Scientific) was added and quenched with 0.5 M H2S04 before reading at 450 nm (HRP). 19 
 20 
Protein expression 21 
N protein was obtained from the James lab at LMB, Cambridge. The N protein used is a 22 
truncated construct of the SARS-CoV-2 N protein comprising residues 48-365 (both ordered 23 
domains with the native linker) with an N terminal uncleavable hexahistidine tag. N was 24 
expressed in E. Coli using autoinducing media for 7h at 37°C and purified using immobilised 25 
metal affinity chromatography (IMAC), size exclusion and heparin chromatography.  26 
 27 
S protein consists of a pre-fusion S ectodomain residues 1-1138 with proline substitutions at 28 
amino acid positions 986 and 987, a GGGG substitution at the furin cleavage site (amino acids 29 
682-685) and an N terminal T4 trimerisation domain followed by a Strep-tag II [17]. The 30 
protein was expressed in 1 L HEK-293F cells (Invitrogen) grown in suspension at a density of 31 
1.5 million cells/mL. The culture was transfected with 325 µg of DNA using PEI-Max (1 mg/mL, 32 
 15 
Polysciences) at a 1:3 ratio. Supernatant was harvested after 7 days and purified using 1 
StrepTactinXT Superflow high capacity 50% suspension according to the manufacturer’s 2 
protocol by gravity flow (IBA Life Sciences).  3 
 4 
The RBD plasmid was obtained from Florian Krammer at Mount Sinai University [18]. Here 5 
the natural N-terminal signal peptide of S is fused to the RBD sequence (319 to 541) and joined 6 
to a C-terminal hexahistidine tag. This protein was expressed in 500 mL HEK-293F cells 7 
(Invitrogen) at a density of 1.5 million cells/mL. The culture was transfected with 1000 µg of 8 
DNA using PEI-Max (1 mg/mL, Polysciences) at a 1:3 ratio. Supernatant was harvested after 7 9 
days and purified using Ni-NTA agarose beads. 10 
 11 
Lateral Flow Immunoassays (LFIA) 12 
We tested seven point-of-care colloidal-gold-based LFIAs detecting IgG and IgM antibodies 13 
against SARS-CoV-2. With the exception of Medomics, all LFIAs were CE IVD marked. Target 14 
antigens were undisclosed proprietary information, but for several of them were known to 15 
be S. LFIAs were run according to manufacturer’s instructions. Typically, 10-20 µl of serum 16 
was added to the LFIA membrane start point, followed by 1-3 drops of supplied buffer. Kits 17 
were run at room temperature for 10 minutes and then immediately scored using a 4-point 18 
scale (negative, borderline, positive, strong positive) for both IgM and IgG. Scoring was 19 
performed independently by two individuals.  20 
 21 
LFIA Distributor/Manufacturer Reference Lot No. 
Accu-Tell COVID-19 
IgG/IgM Cassette AccuBiotech Co., Ltd. ABT-IDT-B352 #2020031701 
COVID-19 (SARS-CoV-2) 
Antibody Test Kit 
Anhui DeepBlue Medical 
Technology Co., Ltd. N/A #20200305 
SARS-CoV-2 IgM/IgG 
ANTIBODY TEST KIT Biohit Healthcare Co., Ltd. N/A SA200401 
GenBody COVID-19 
IgM/IgG GenBody Inc. COVI025 FJFN25201 
COVID-19 Spring IgM/IgG 
Rapid Test Cassette 
Spring Healthcare Services 
AG ERCSSO5310 N01G26T 
COVID-19 IgG/IgM Rapid 
Test Cassette 
SureScreen Diagnostics 
Co., Ltd. COVID19C COV20030045 
 16 
 1 
 2 
Chemiluminescence-based Immunoassay 3 
The SARS-CoV-2 Ab Diagnostic Test Kit (Shenzen Watmind Medical Co., Ltd.) detecting total 4 
antibody against SARS-CoV-2 was run on the Chemical Luminescence Immunity Analyzer 5 
MF02 (Shenzen Watmind Medical Co., Ltd). The platform was calibrated with a supplied 6 
control cartridge daily prior to testing. Panel samples were analysed according to 7 
manufacturer’s instructions. Results equal to and below 1.0 AU (arbitrary units) /ml were 8 
negative, scores above 1.0 AU/ml were deemed positive. For comparison to other 9 
immunoassays, scores between 1<10 AU/ml were deemed positive, scores >10 AU/ml were 10 
deemed a strong positive.  11 
 12 
Enzyme-linked Immunosorbent Assay (ELISA) 13 
Two commercial ELISAs detecting IgA (EI 2606-9601 A) or IgG (EI 2606-9601 G) antibodies to 14 
the SARS-CoV-2 S1 protein were obtained from EUROIMMUN Medizinische Labordiagnostika 15 
AG. Serum samples were tested according to manufacturer’s instructions. Absorbance was 16 
measured on a Multiskan FC (SkanIt Software 5.0 for Microplate Readers RE. ver. 5.0.0.42) at 17 
a wavelength of 450 nm with a reference wavelength of 630 nm.  18 
 19 
Statistical Analysis 20 
Expected binomial exact 95% confidence intervals were calculated on Prism 8.0 using 21 
Wilson/Brown statistical analysis. 22 
 23 
 24 
 25 
 26 
  27 
Rapid IgM-IgG Combined 
Antibody Test Kit for SARS-
CoV-2 
Jiangsu Medomics Medical 
Technology Co. Ltd. N/A #2020050305 
 17 
FIGURE LEGENDS 1 
 2 
Figure 1 3 
Validation of a SARS-CoV-2 ELISA for measuring IgG and IgM in Covid-19 patients.  4 
(A) 320 pre-pandemic serum/plasma samples were assayed for IgM and IgG against SARS-5 
CoV-2 stabilised and uncleaved S protein, the RBD from S, and N. Sera/plasma came from 6 
emergency admissions to St Thomas’ hospital in March 2019 (STH healthy, n=105), individuals 7 
with acute EBV infection (n=9), vaccine trials (HIRD cohort [18], n=44), cancer patients (n=61), 8 
and healthy volunteers (UCL healthy, n=101). The IgM and IgG binding were compared to that 9 
of 24 SARS-CoV-2 PCR positive ICU patients collected in March and April 2020. Sera and 10 
plasma were diluted to 1:50 and 1:25 respectively. The values reported are the fold-change 11 
in OD above background. (B) Analysis of IgG binding of pre-Covid-19 human sera/plasma 12 
(n=320) compared to sera from SARS-CoV-2 infected patients (n=24) revealed that IgG against 13 
both N and S distinguished these two groups. The fold-change above background for IgG 14 
against N was plotted against the fold-change above background for S IgG binding and RBD 15 
IgG binding for each individual. (C) Analysis of IgM binding of pre-Covid-19 human 16 
sera/plasma (n=320) compared to sera from SARS-CoV-2 infected patients (n=24). 17 
 18 
Figure 2 19 
Comparison of nine serological assays for the detection of anti-SARS CoV-2 IgM and IgA. 20 
110 serum samples from 87 individuals with confirmed SARS-CoV-2 infection (RNA+ by RT-21 
PCR) were assayed for anti-SARS CoV-2 IgM using an in-house anti-S ELISA (shown in the graph 22 
across the top of each panel, black bars), seven colloidal gold lateral flow tests (Deep Blue, 23 
Accu-Tell, GenBody, SureScreen, Spring, Biohit and Medomics), and for anti-S1 IgA using a 24 
commercial ELISA (EUROIMMUN). The threshold for a positive result in the in-house ELISA is 25 
set at 4-fold above background, as indicated by the red dashed line. Results for the other tests 26 
are represented as heatmaps, with colour intensity corresponding to strength of signal for 27 
each test. For EUROIMMUN, scores of <0.8 are negative, ³0.8 to <1.1 are borderline, ³1.2 to 28 
<4 are positive, and ³4 are strong positive.  Samples are grouped according to days post onset 29 
of COVID-19 symptoms, and squares aligned in columns under each bar of the graph show 30 
results for a single serum sample. Yellow circles indicate samples from 10 days or more POS 31 
that were negative by ELISA and in at least 6 other tests, as detailed in the text. 32 
 33 
Figure 3 34 
Comparison of ten serological assays for the detection of anti-SARS CoV-2 IgG. 35 
As for in Figure 2, the same 110 serum samples were assessed for the presence of anti-SARS 36 
CoV-2 IgG.  Each sample was assayed using an in-house anti-S ELISA (shown in the graph 37 
across the top of each panel, black bars), seven colloidal gold lateral flow tests (Deep Blue, 38 
Accu-Tell, GenBody, SureScreen, Spring, Biohit and Medomics), and a commercial ELISA 39 
(EUROIMMUN). A chemiluminescent assay for total anti-SARS CoV-2 IgM, IgG and IgA 40 
(Watmind) was also included. The threshold for a positive result in the in-house ELISA is set 41 
at 4-fold above background, as indicated by the red dashed line. Results for the other tests 42 
are represented as heatmaps, with colour intensity corresponding to strength of signal for 43 
each test. For EUROIMMUN, scores of <0.8 are negative, ³0.8 to <1.1 are borderline, ³1.2 to 44 
<4 are positive, and ³4 are strong positive. For Watmind, scores <1 are negative, >1 to <10 45 
 18 
are positive, and >10 to 100 are strong positive. Yellow circles indicate samples from 10 days 1 
or more POS that were negative by ELISA and in all commercial tests. 2 
 3 
Figure 4 4 
Comparative tables  5 
Serological assays were compared and the percentage agreement between the results of 6 
each of the samples in the assays is represented within each box. 7 
 8 
Figure 5 9 
Sensitivity and specificity comparison of serological assays  10 
(A) Specificity was determined for each serological assay using a panel of 50 pre-pandemic 11 
serum samples from March 2019. Overall sensitivity was determined for each serological 12 
assay, based on results for 110 serum samples from known SARS-CoV-2-positive individuals 13 
(shown in Figures 3 and 4). For the lateral flow assays, a positive result for IgM, IgG or both is 14 
considered positive. For the EUROIMMUN and in-house ELISAs, sensitivities for IgA, IgM and 15 
IgG are calculated separately. (B) Sensitivity and 95% confidence intervals (vertical lines) were 16 
determined for each serological assay at increasing days POS. 95% sensitivity is indicated by 17 
the horizontal dashed line. Results for each test were categorised according to whether the 18 
serum sample was from <10, ³10, ³14, or ³20 days POS.  19 
 20 
Figure 6 21 
Antibody detection over increasing days POS and illness severity 22 
(A) In-house ELISA results for anti-SARS-CoV-2 IgM and IgG were grouped by days POS and 23 
severity of illness, with 0 indicating mild illness (requiring no respiratory support) and 5 24 
indicating critical (requiring ECMO) (see materials and methods for full classification). The 4-25 
fold threshold for a positive result is shown as a dashed line on each graph. Median values 26 
are shown as red lines. (B) Sequential serum samples from five individuals were assayed for 27 
the development of anti-SARS-CoV-2 IgM and IgG. All five individuals were hospitalised with 28 
COVID-19 symptoms and confirmed positive for SARS-CoV-2 RNA by RT-PCR. A semi-29 
quantitative in-house ELISA detecting anti-S antibodies (shown in graphs) and the SureScreen 30 
lateral flow assay (shown in heatmaps below the graphs) were compared for their detection 31 
of anti-SARS-CoV-2 in the same serum samples. Days POS are indicated for each sample. (C) 32 
Images of the lateral flow test results for patient 3 are shown. 33 
 34 
 35 
Supplementary Figure A 36 
Serological assays were compared for IgM or IgG (left and right panels, respectively), and the 37 
percentage agreement between each of the samples in the assays is represented within each 38 
box. 39 
 40 
Supplementary Figure B 41 
Overall sensitivity (A) and specificity (B) were determined for each serological assay as in 42 
Figure 5.  Sensitivity was determined for each serological assay at increasing days POS (C), or 43 
severity of illness (D). Results for each test were either categorised according to whether the 44 
serum sample was from <10, ³10, ³14, or ³20 days POS, or severity of illness, with 0 indicating 45 
mild illness (requiring no respiratory support) and 5 indicating critical (requiring ECMO) (see 46 
 19 
Materials and Methods for full classification). 95% confidence intervals are shown for each 1 
assay in all panels (Wilson/Brown expected binomial). 2 
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Table 1. Baseline of patient cohort clinical characteristics  
 
Demographics 
Mean Age (years)  58.2 +/- 16.6 
Female 29 (33.3%) 
Level of Respiratory Support 
No support 11 (12.6%) 
Supplemental oxygen 23 (26.4%) 
Non- invasive ventilation 1 (1.1%) 
Mechanical ventilation 46 (52.8%) 
ECMO 6 (6.9%) 
Disease Severity 
Level 0 11 (12.6%) 
Level 1 15 (17.2%) 
Level 2 4 (4.6%) 
Level 3 3 (3.4%) 
Level 4 48 (55.2%) 
Level 5 6 (6.9) 
Died 21 (24.1%) 
Comorbidities 
Hypertension 40 (45.9%) 
Obesity 38 (43.7%) 
T2DM 26 (29.9%) 
Hypercholesterolaemia 10 (11.5%) 
Chronic respiratory disease * 12 (13.8%) 
CKD 5 (5.7%) 
ESRF 4 (4.6%) 
Renal transplant 3 (3.4%) 
Hypothyroidism  3 (3.4%) 
T1DM 2 (2.3%) 
HIV 1 (1.1%) 
    
* COPD, interstitial lung disease, bronchiectasis, 
asthma 
 
Supplementary Table 1. Sensitivity and specificity of in-house ELISAs during development phase, with 95% CI. 
 
 
 
 
 
  
Total N Negatives % 95% CI Total N Positives % 95% CI
In-house IgM - N 320 200 62.50 57.08 - 67.63 24 22 91.67 74.15 - 98.52
In-house IgG - N 320 271 84.69 80.33 - 88.22 24 24 100.00 86.20 - 100.0
In-house IgM - S 320 291 90.94 87.29 - 93.62 24 24 100.00 86.20 - 100.0
In-house IgG - S 320 316 98.75 96.83 - 99.51 24 24 100.00 86.20 - 100.0
In-house IgM - RBD 320 305 95.31 92.41 - 97.14 24 24 100.00 86.20 - 100.0
In-house IgG - RBD 320 319 99.69 98.25 - 99.98 24 24 100.00 86.20 - 100.0
In-house IgM N+S 320 301 94.06 90.91 - 96.17 24 22 91.67 74.15 - 98.52
In-house IgG N+S 320 320 100.00 98.81 - 100.0 24 24 100.00 86.20 - 100.0
In-house IgM N+RBD 320 309 96.56 93.95 - 98.07 24 22 91.67 74.15 - 98.52
In-house IgG N+RBD 320 320 100.00 98.81 - 100.0 24 24 100.00 86.20 - 100.0
Specificity Sensitivity
Supplementary Table 2. Specificity of immunoassays platforms determined pre-pandemic serum samples from March 2019. 
 
 
 
 
New Supplementary Table 3. Specificity of selected lateral flow immunoassays determined on an extended panel of pre-pandemic serum 
samples from March 2019. 
 
 
 
 
 
 
 
 
 
 
Total N Negative % 95% CI
Deep Blue 50 41 82.00 69.20 - 90.23
Accu-Tell 50 49 98.00 89.50 - 99.90
GenBody 50 50 100.00 92.87 - 100.0
SureScreen 50 50 100.00 92.87 - 100.0
Spring 50 49 98.00 89.50 - 99.90
Biohit 50 47 94.00 83.78 - 98.36
Medomics 50 49 98.00 89.50 - 99.90
Watmind 50 41 82.00 69.20 - 90.23
EUROIMMUN IgA 50 50 100.00 92.87 - 100.0
EUROIMMUN IgG 50 50 100.00 92.87 - 100.0
In-house IgM S 105 104 99.05 94.80 - 99.95
In-house IgG S 105 105 100.00 96.47 - 100.0
Specificity
Total N Negative % 95% CI
SureScreen 200 199 99.50 97.22 - 99.97
Spring 145 142 97.93 94.09 - 99.44
Biohit 200 193 96.50 92.95 - 98.29
Medomics 142 136 95.77 91.09 - 98.05
Specificity
Supplementary Table 4. Sensitivity of different platforms determined on specimens from patients with positive SARS-CoV-2 RT-PCR by days 
POS 
 
 
 
Supplementary Table 5. Sensitivity of different platforms determined on specimens from patients with positive SARS-CoV-2 RT-PCR by disease 
severity 
 
 
Total N Positive % 95% CI Total N Positive % 95% CI Total N Positive % 95% CI Total N Positive % 95% CI Total N Positive % 95% CI
Deep Blue 110 96 87.27 79.76 - 92.27 38 30 78.95 63.65 - 88.93 72 66 91.67 82.99 - 96.12 54 51 94.44 84.89 - 98.49 28 28 100.00 87.94 - 100.0
Accu-Tell 110 93 84.55 76.64 - 90.12 38 29 76.32 60.79 - 87.01 72 64 88.89 79.58 - 94.26 54 49 90.74 80.09 - 95.98 28 27 96.43 82.29 - 99.82
GenBody 110 69 62.73 53.41 - 71.19 38 13 34.21 21.21 - 50.11 72 56 77.78 66.91 - 85.83 54 43 79.63 67.10 - 88.23 28 25 89.29 72.80 - 96.29
SureScreen 110 89 80.91 72.57 -87.16 38 27 71.05 55.24 - 83.00 72 62 86.11 76.29 - 92.28 54 49 90.74 80.09 - 95.98 28 28 100.00 87.94 - 100.0
Spring 110 93 84.55 76.64 - 90.12 38 29 76.32 60.79 - 87.01 72 64 88.89 79.58 - 94.26 54 50 92.59 82.45 - 97.08 28 28 100.00 87.94 - 100.0
Biohit 110 83 75.45 66.64 - 82.55 38 22 57.89 42.19 - 72.15 72 61 84.72 74.68 - 91.25 54 47 87.04 75.58 - 93.58 28 27 96.43 82.29 - 99.82
Medomics 110 81 73.64 64.71 - 80.97 38 20 52.63 37.26 - 67.52 72 61 84.72 74.68 - 91.25 54 48 88.89 77.81 - 94.81 28 27 96.43 82.29 - 99.82
Watmind 110 67 60.91 51.57 - 69.51 38 14 36.84 23.38 - 52.72 72 53 73.61 62.42 - 82.41 54 42 77.78 65.06 - 86.80 28 24 85.71 68.51 - 94.30
EUROIMMUN IgA 110 87 79.09 70.57 - 85.64 38 25 65.79 49.89 - 78.79 72 62 86.11 76.29 - 92.28 54 48 88.89 77.81 - 94.81 28 28 100.00 87.94 - 100.0
EUROIMMUN IgG 110 66 60.00 50.66 - 68.67 38 10 26.32 14.97 - 42.01 72 56 77.78 66.91 - 85.83 54 46 85.19 73.40 - 92.30 28 27 96.43 82.29 - 99.82
In-house IgM S 110 82 74.55 65.67 - 81.76 38 21 55.26 39.71 - 69.85 72 61 84.72 74.68 - 91.25 54 48 88.89 77.81 - 94.81 28 28 100.00 87.94 - 100.0
In-house IgG S 110 81 70.91 61.83 - 78.58 38 20 52.63 37.26 - 67.52 72 61 84.72 74.68 - 91.25 54 47 87.04 75.58 - 93.58 28 27 96.43 82.29 - 99.82
OVERALL < 10 days ≥ 10 days ≥ 14 days ≥ 20 days
Total N Positive % 95% CI Total N Positive % 95% CI Total N Positive % 95% CI Total N Positive % 95% CI
Deep Blue 11 4 36.36 15.17 - 64.62 23 22 95.65 79.01 - 99.78 57 51 89.47 78.88 - 95.09 19 19 100.00 83.18 - 100.0
Accu-Tell 11 3 27.27 9.75 - 56.56 23 21 91.30 73.20 - 98.45 57 50 87.72 76.75 - 93.92 19 19 100.00 83.18 - 100.0
GenBody 11 1 9.09 0.46 - 37.74 23 16 69.57 49.13 - 84.40 57 33 57.89 44.98 - 69.81 19 19 100.00 83.18 - 100.0
SureScreen 11 3 27.27 9.75 - 56.56 23 19 82.61 62.86 - 93.02 57 48 84.21 72.64 - 91.46 19 19 100.00 83.18 - 100.0
Spring 11 3 27.27 9.75 - 56.56 23 21 91.30 73.20 - 98.45 57 50 87.72 76.75 - 93.92 19 19 100.00 83.18 - 100.0
Biohit 11 3 27.27 9.75 - 56.56 23 16 69.57 49.13 - 84.40 57 45 78.95 66.71 - 87.53 19 19 100.00 83.18 - 100.0
Medomics 11 3 27.27 9.75 - 56.56 23 17 73.91 53.53 - 87.45 57 43 75.44 62.90 - 84.77 19 18 94.74 75.36 - 99.73
Watmind 11 1 9.09 0.46 - 37.74 23 13 56.52 36.81 - 74.37 57 37 64.91 51.94 - 76.00 19 16 84.21 62.43 - 94.48
EUROIMMUN IgA 11 4 36.36 15.17 - 64.62 23 20 86.96 67.87 - 95.46 57 44 77.19 64.79 - 86.16 19 19 100.00 83.18 - 100.0
EUROIMMUN IgG 11 2 18.18 3.23 - 47.70 23 12 52.17 32.96 - 70.76 57 34 59.65 46.70 - 71.38 19 18 94.74 75.36 - 99.73
In-house IgM S 11 3 27.27 9.75 - 56.56 23 19 82.61 62.86 - 93.02 57 41 71.93 59.17 - 81.92 19 19 100.00 83.18 - 100.0
In-house IgG S 11 3 27.27 9.75 - 56.56 23 18 78.26 58.10 - 90.34 57 41 71.93 59.17 - 81.92 19 19 100.00 83.18 - 100.0
Level 0 Levels 1-3 Level 4 Level 5
